The clinical response to minocycline in multiple sclerosis is accompanied by beneficial immune changes: a pilot study
- 9 February 2007
- journal article
- clinical trial
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 13 (4), 517-526
- https://doi.org/10.1177/1352458506070319
Abstract
Minocycline has immunomodulatory and neuroprotective activities in vitro and in an animal model of multiple sclerosis (MS). We have previously reported that minocycline decreased gadolinium-enhancing activity over six months in a small trial of patients with active relapsing-remitting MS (RRMS). Here we report the impact of oral minocycline on clinical and magnetic resonance imaging (MRI) outcomes and serum immune molecules in this cohort over 24 months of open-label minocycline treatment. Despite a moderately high pretreatment annualized relapse rate (1.3/year pre-enrolment; 1.2/year during a three-month baseline period) prior to treatment, no relapses occurred between months 6 and 24. Also, despite very active MRI activity pretreatment (19/40 scans had gadolinium-enhancing activity during a three-month run-in), the only patient with gadolinium-enhancing lesions on MRI at 12 and 24 months was on half-dose minocycline. Levels of the p40 subunit of interleukin (IL)-12, which at high levels might antagonize the proinflammatory IL-12 receptor, were elevated over 18 months of treatment, as were levels of soluble vascular cell adhesion molecule-1. The activity of matrix metalloproteinase-9 was decreased by treatment. Thus, clinical and MRI outcomes are supported by systemic immunological changes and call for further investigation of minocycline in MS. Multiple Sclerosis 2007; 13: 517-526. http://msj.sagepub.comKeywords
This publication has 30 references indexed in Scilit:
- Minocycline reduces gadolinium‐enhancing magnetic resonance imaging lesions in multiple sclerosisAnnals of Neurology, 2004
- An interleukin 12 p40-IgG2b fusion protein abrogates T cell mediated inflammation: anti-inflammatory activity in Crohn's disease and experimental colitis in vivoGut, 2004
- The power of combinatorial immunology: IL-12 and IL-12-related dimeric cytokines in infectious diseasesMedical Microbiology and Immunology, 2004
- Effect of minocycline in experimental autoimmune encephalomyelitisAnnals of Neurology, 2002
- Soluble Intercellular Adhesion Molecule-1 (sICAM-1) in serum and cerebrospinal fluid of demyelinating diseases of the central and peripheral nervous systemMultiple Sclerosis Journal, 1998
- The variability of manual and computer assisted quantification of multiple sclerosis lesion volumesMedical Physics, 1996
- Differential expression of mRNA encoding interleukin‐12 p35 and p40 subunits in situEuropean Journal of Immunology, 1994
- Computer-assisted identification and quantification of multiple sclerosis lesions in MR imaging volumes in the brainJournal of Magnetic Resonance Imaging, 1994
- The interleukin‐12 subunit p40 specifically inhibits effects of the interleukin‐12 heterodimerEuropean Journal of Immunology, 1993
- MINOCYCLINE EXCRETION AND DISTRIBUTION IN RELATION TO RENAL FUNCTION IN MANClinical and Experimental Pharmacology and Physiology, 1974